SK-Pharma

SK-Pharma is a commercial-stage pharmaceutical company focused on value-added medicines, complex generics, specialty products, orphan drugs, and selected biosimilar products. The company operates as a group centered around K.S.Kim International and emphasizes regulatory execution, market access, distribution, and first-to-market launches across Israel and international markets. Its marketed portfolio spans oncology, ADHD, ophthalmology, anti-infectives, and other specialty categories, and the company states it has built a portfolio of more than 100 products. SK-Pharma also highlights data-driven product selection and supply-chain optimization through its DrugsIntel technology initiative. The business appears oriented more toward commercialization, registration, licensing, and supply of medicines than toward discovery-stage R&D.